Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across Canada
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Friday 10th, April 2026
External Deadline: Wednesday 15th, April 2026
Description
Pfizer and CCC (‘the collaborators’) are jointly issuing this RFP. This program aims to support access to Research or QI project funding described in ‘Funding Opportunities’ below. The goal is to enable applicants to pursue innovative approaches to optimize biomarker testing strategies at the applicants’ centre. Funding and general oversight of the funded projects will be provided directly from Pfizer on behalf of the collaborator.
For all Research and QI proposals, the grant requester and ultimately, the grantee, is responsible for the design, implementation, sponsorship and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. As the commercial supporter, Pfizer colleagues must not be involved in any aspect of project development or implementation.
Grants will be awarded in support of organizations/institutions working to improve the competence and performance of both the healthcare providers and healthcare systems in which they work with the goal of optimizing the care and outcomes of cancer patients.
Date RFP Issued: January 15, 2026
Geographic Scope: Canada
Clinical Area: Colorectal cancer (mCRC)
Link to full RFP: Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across Canada
Application Due Date: April 15, 2026
Specific Area of Interest: The intent of this RFP is to encourage the applicant Canadian organizations and institutions to pursue innovative approaches for Research or QI projects that aim to optimize biomarker testing for patients in CRC at the applicants’ centre. Applicants are invited to implement innovative ideas with the goal of creating a path for sustainable biomarker testing for mCRC patients in Canada.
- – All projects, whether Research or QI, must include a component that addresses metastatic colorectal cancer (mCRC) patient needs.
- – In addition to mCRC, applicants may submit project proposals that encompass biomarker testing in earlier stages of CRC, where clinically relevant, or in other tumour types (for example, projects assessing implementation of tumor agnostic or multi-tumour NGS panels).
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Ying Ying (Elena) Huang (yingying.huang@pfizer.com).